Showing 7861-7880 of 8819 for: Cochrane Systematic Reviews Back
- Systemic interventions for recurrent aphthous stomatitis (mouth ulcers)
Cochrane Systematic Reviews, 13-Aug-2012
Recurrent aphthous stomatitis (RAS) is the most frequent form of oral ulceration, characterised by recurrent oral mucosal ulceration in an otherwise healthy individual. At its worst RAS can cause significant difficulties in eating and drinking. Treatment
- Systemic interventions for severe atopic and vernal keratoconjunctivitis in children and young people up to the age of 16 years
Cochrane Systematic Reviews, 21-Oct-2020
Atopic keratoconjunctivitis (AKC) and vernal keratoconjunctivitis (VKC) are severe and potentially sight-threatening allergic eye diseases characterised by chronic inflammation of the ocular surface. Both topical and systemic treatments are used. This Coc
- Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
Cochrane Systematic Reviews, 11-Mar-2022
Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome are rare, severe cutaneous adverse reactions usually triggered by medications. In addition to tertiary-level supportive care, various systemic therapies have be
- Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis
Cochrane Systematic Reviews, 23-May-2022
Psoriasis is an immune-mediated disease with either skin or joints manifestations, or both, and it has a major impact on quality of life. Although there is currently no cure for psoriasis, various treatment strategies allow sustained control of disease si
- Systemic prokinetic pharmacologic treatment for postoperative adynamic ileus following abdominal surgery in adults
Cochrane Systematic Reviews, 9-Aug-2009
Postoperative adynamic bowel atony interferes with recovery following abdominal surgery. Prokinetic pharmacologic drugs are widely used to accelerate postoperative recovery.
- Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Cochrane Systematic Reviews, 5-Sep-2014
Neovascular age-related macular degeneration (AMD) is the leading cause of legal blindness in elderly populations of industrialised countries. Bevacizumab (Avastin®) and ranibizumab (Lucentis®) are targeted biological drugs (a monoclonal antibody) that in
- Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast cancer
Cochrane Systematic Reviews, 10-Jan-2022
Adjuvant aromatase inhibitors (AI) improve survival compared to tamoxifen in postmenopausal women with hormone receptor-positive stage I to III breast cancer. In approximately half of these women, AI are associated with aromatase inhibitor-induced musculo
- Systemic therapy for treating locoregional recurrence in women with breast cancer
Cochrane Systematic Reviews, 10-Jun-2008
Between 10% and 35% of women with operable breast cancer will experience an isolated locoregional recurrence following their primary treatment. There is currently no good evidence that adjuvant systemic treatment is effective in this situation and there i
- Systemic treatment for blepharokeratoconjunctivitis in children
Cochrane Systematic Reviews, 26-May-2016
Blepharokeratoconjunctivitis (BKC) is a type of inflammation of the surface of the eye and eyelids which can affect children and adults. BKC involves changes of the eyelids, dysfunction of the meibomian glands, and inflammation of the conjunctiva and corn
- Systemic treatments for eczema: a network meta‐analysis
Cochrane Systematic Reviews, 14-Sep-2020
Eczema is a common and chronic, relapsing, inflammatory skin disorder. It seriously impacts quality of life and economic outcomes, especially for those with moderate to severe eczema. Various treatments allow sustained control of the disease; however, the
- Systemic treatments for metastatic cutaneous melanoma
Cochrane Systematic Reviews, 3-Jun-2014
Systemic therapies for metastatic cutaneous melanoma, the most aggressive of all skin cancers, remain disappointing. Few lasting remissions are achieved and the therapeutic aim remains one of palliation.
- Systemic treatments for metastatic cutaneous melanoma
Cochrane Systematic Reviews, 6-Feb-2018
The prognosis of people with metastatic cutaneous melanoma, a skin cancer, is generally poor. Recently, new classes of drugs (e.g. immune checkpoint inhibitors and small-molecule targeted drugs) have significantly improved patient prognosis, which has dra
- Systemic treatments for the prevention of venous thrombo-embolic events in paediatric cancer patients with tunnelled central venous catheters
Cochrane Systematic Reviews, 10-Sep-2013
Venous thrombo-embolic events (VTEs) occur in 2.2% to 14% of paediatric cancer patients and cause significant morbidity and mortality. The malignant disease itself, the cancer treatment and the presence of central venous catheters (CVCs) increase the risk
- Systems for routine surveillance in people with diabetes mellitus
Cochrane Systematic Reviews, 10-Nov-2008
There is wide variation in the extent of general practice involvement in diabetes care.
- Tacrine for Alzheimer's disease
Cochrane Systematic Reviews, 6-Nov-2008
Tacrine is one of the first drugs to be widely marketed for the loss of memory and intellectual decline in Alzheimer's disease, often accompanied by abnormal behaviour and physical decline. The alleged success of tacrine in the treatment of these symptoms
- Tacrolimus (FK506) for induction of remission in corticosteroid‐refractory ulcerative colitis
Cochrane Systematic Reviews, 7-Apr-2022
There are a limited number of treatment options for people with corticosteroid-refractory ulcerative colitis. Animal models of inflammatory bowel disease and uncontrolled studies in humans suggest that tacrolimus may be an effective treatment for ulcerati
- Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients
Cochrane Systematic Reviews, 25-Aug-2008
Kidney transplantation is the treatment of choice for most patients with end-stage renal disease (ESRD). Standard protocols in use typically involve three drug groups each directed to a site in the T-cell activation or proliferation cascade which are cent
- Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients
Cochrane Systematic Reviews, 29-Apr-2013
Lung transplantation is a well-accepted treatment for people with most end-stage lung diseases. Although both tacrolimus and cyclosporin are used as primary immunosuppressive agents in lung transplant recipients, it is unclear which of these drugs is bett
- Tafenoquine for preventing relapse in people with Plasmodium vivax malaria
Cochrane Systematic Reviews, 24-Apr-2015
Plasmodium vivax malaria is widespread, and the persistent liver stage causes relapse of the disease which contributes to continued P. vivax transmission. Primaquine is currently the only drug that cures the parasite liver stage, but requires 14 days to
- Tai Chi for chronic obstructive pulmonary disease (COPD)
Cochrane Systematic Reviews, 7-Jun-2016
Tai Chi, a systematic callisthenic exercise first developed in ancient China, involves a series of slow and rhythmic circular motions. It emphasises use of 'mind' or concentration to control breathing and circular body motions to facilitate flow of intern
